Targeting MutT Homolog 1 (MTH1) for Breast Cancer Suppression by Using a Novel MTH1 Inhibitor MA-24 with Tumor-Selective Toxicity.

Nannan KangJun MaYuling HuRongrong DiLei WangXuanling ZhangYisheng LaiYu Liu

Published in: Pharmaceuticals (Basel, Switzerland) (2024)

MA-24 possesses a broad spectrum of breast cancer cytotoxicity and offered valuable insights for overcoming the challenges of chemotherapy-related toxicity, which holds great potential for the further development MA-24 as an anti-cancer drug.

Keyphrases

oxidative stress
cancer therapy
breast cancer risk
drug delivery
oxide nanoparticles
risk assessment